Table 2.
High frequencies of co-occurring NAT2 and ATP7B risk genotypes in patients with anti-tuberculosis drug-induced liver injury.
| Risk Genotypes | NAT2 UA | ATP7B 832 R/R | NAT2 UA + ATP7B 832 R/R | ||||
|---|---|---|---|---|---|---|---|
| n | % | n | % | n | % | ||
| Discovery cohort (n = 112) | Case | 11 | 31.4 | 11 | 31.4 | 6 | 17.1 |
| Control | 3 | 3.9 | 10 | 13 | 0 | 0 | |
| OR [95% CI] | 11.02 [2.62–66.67] | 3.04 [1.03–9.13] | >66.4 | ||||
| P value | 1.4 × 10−4 | 0.035 | 6.8 × 10−4 | ||||
| Replication cohort (n = 165) | Case | 9 | 24.3 | 9 | 24.3 | 4 | 10.8 |
| Control | 10 | 7.8 | 22 | 17.2 | 1 | 0.78 | |
| OR [95% CI] | 3.75 [1.23–11.41] | 1.54 [0.56–3.98] | 15.06 [1.43–760] | ||||
| P value | 0.015 | 0.34 | 9.3 × 10−3 | ||||
| Combined cohort (n = 277) | Case | 20 | 27.8 | 20 | 27.8 | 10 | 13.9 |
| Control | 13 | 6.3 | 32 | 15.6 | 1 | 0.48 | |
| OR [95% CI] | 5.63 [2.48–13.22] | 2.07 [1.03–4.10] | 32.45 [4.46–1424] | ||||
| P value | 7.2 × 10−6 | 0.034 | 7.5 × 10−6 | ||||
| Population control (n = 1,048) | 129 | 12.3 | 147 | 14 | 19 | 1.8 | |
| OR [95% CI]a | 2.73 [1.50–4.84] | 2.35 [1.29–4.15] | 8.70 [3.46–20.67] | ||||
| P valuea | 8.8 × 10−4 | 0.003 | 4.8 × 10−6 | ||||
aComparison with the combined cohort.